The value of combined detection with MMP9 and uPA in prognosis of pancreatic carcinoma

doi:10.3760/cma.j.issn.1673422X.2015.03.005

Abstract

Abstract: ObjectiveTo explore the value of combined detection with MMP9 and uPA in the prognosis of pancreatic carcinoma. MethodsBy immunohistochemistry PV methods，the expression of MMP9 and uPA was respectively studied in 63 surgical specimens of primary pancreatic carcinoma and the survival time of patients with pancreatic carcinoma was analysed. ResultsThe expressions of MMP9 and uPA were positively related （r=0.573，P=0.000）. The expression of MMP9 and uPA significantly correlated with differentiation（r=-0.271，P=0.032；r=-0.333，P=0.008）, TNM stages（r=-0.449，P=0.000；r=-0.430，P=0.000）and lymph node metastasis（r=0.329，P=0.009；r=0.400，P=0.001）, separately. The expression of MMP9 had also a significant correlation with tumer size（r=-0.297，P=0.018）and distant metastasis（r=0.320，P=0.011）．Univariate analysis identified that tumor size（χ2=8.766，P=0.012）,differentiation（χ2=29.050，P=0.000）,clinical stage（χ2=24.940，P=0.000）,distant metastasis（χ2=12.846，P=0.000）,lymph node metastasis（χ2=15.457，P=0.000）,MMP9（χ2=32.700,P=0.000）and uPA（χ2=41.495,P=0.000）were significantly associated with prognosis. KaplanMeier survival analysis showed that 1year survival rate of patients with MMP9 (-)，uPA (-)were significantly longer than that of the patients with MMP9 (+)，uPA (+),respectively(χ2=32.700，P=0.000；χ2=41.495，P=0.000)；1year survival rate of patients with MMP9 (-)/uPA(-)was significantly longer than the others(Logrank test，χ2= 54.892, P=0.000).COX regression revealed that differentiation (RR=2.315，P=0.004),clinical stage（RR=1.694,P=0.002）,MMP9（RR=0.165,P=0.000） and uPA（RR=0.244,P=0.007）was independent prognostic factors in pancreatic carcinoma. ConclusionThey may have a synergistic function in the the process of growth and invasion in pancreatic cancer between MMP9 and uPA, and the posssible mechanism is that uPA activate degradation of MMP9, which is not favorable to prognosis.Combined analysis of MMP9 and uPA may lead to a more reliable prognostic estimation,as the beneficial supplement of the differentiation, and clinical stage to judge the prognosis of pancreatic cancer.

Key words: Pancreatic neoplasms, Prognosis, Matrix metalloproteinase 9, Urinary plasminogen actirator

Li-Shi-Jie, HU Jun-Hong, XIE Yong-Zheng, REN Xue-Qun, JIA Fu-Xin, LIU Jiang-Wei. The value of combined detection with MMP9 and uPA in prognosis of pancreatic carcinoma[J]. Journal of International Oncology, 2015, 42(3): 177-181.

References

［1］胡育新, 李平, 刘宝姝, 等. 胰腺癌组织中基质金属蛋白酶7(MMP7)的表达［J］. 癌症, 2000, 19(6): 521523. ［2］ Fukushima H, Yamamoto H, Itoh F, et al. Association of matrilysin mRNA expression with Kras mutations and progression in pancreatic ductal adenocarcinomas［J］. Carcinogenesi, 2001, 22(7):10491052. ［3］ Friess H, Guo XZ, Berberat P, et al. Reduced KAI1 expression in pancreatic canceris associated with lymph node distant metastases［J］. Int J Cancer, 1998, 79(4):349355. ［4］黄陈，裘正军，孙晶, 等. PSTAT3与MMP2、MMP9在胰腺癌组织中表达及其临床意义［J］. 2007, 13（12）:851853. ［5］闫慧明，郭艳丽，郑启昌, 等. 应用组织芯片技术研究uPA和uPAR在胰腺癌中的表达［J］. 2004, 35（5）:455457. ［6］ Chang C, Werb Z. The mang faces of metalloproteases：cell growth, invasion, angiogenesis and metastasis［J］. Trends Cell Biol, 2001, 11(11):3741. ［7］ Somiari SB, Shriver CD, Heckman C, et al. Plasma concentration and activity of matrix metalloproteinase2 and9 in patients with breast disease, breast cancer and at risk of developing breast cancer［J］. Cancer Lett, 2006, 233(1):98107. ［8］ Littlepage LE, Sternlicht MD, Rougier N, et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression［J］. Cancer Res, 2010, 70 (6) :22242234. ［9］ Tummalapalli P, Spomar D, Gondi CS, et al. RNAimediated abrogation of cathepsin B and MMP9 gene expression in a malignant meningioma cell line leads to decreased tumor growth,invasion and angiogenesis［J］. Int J Oncol, 2007, 31(5):10391050. ［10］蔡良真, 支梅芬, 何文艳. 鼻咽癌组织 KiSS1和MMP9表达与淋巴结转移关系的研究［J］. 中华肿瘤防治杂志, 2010, 17 (7):495497. ［11］干文娟, 刘峰, 冯一中. 胰腺癌组织中基质金属蛋白酶MMP9的表达及其临床意义［J］. 苏州大学学报:医学版, 2012, 32(6): 849852. ［12］李春龙，崔云甫, 牡雪飞, 等. VEGF和MMP9在胰腺癌侵袭转移中的表达及临床意义［J］. 世界华人消化杂志, 2008, 16(9):10121016. ［13］张凤梅, 李胜水, 李双标, 等. ILK、MMP9在胰腺癌及其侵袭转移中的表达［J］.诊断病理学杂志, 2013, 206(4)：236238. ［14］贾富鑫, 刘江伟, 张东, 等. S100A4和uPA的表达及其与胰腺癌预后关系的研究［J］.国际肿瘤学杂志, 2011, 38(11): 868872. ［15］ Tsuna M, Kageyama S, Fukuoka J, et al. Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma［J］. Anticancer Res, 2009, 29(7): 25472554. ［16］寇有为, 邵华, 王强. MMP9、uPA及CD34与胃癌侵袭和转移及其相关性［J］. 现代肿瘤医学, 2011, 19(08): 16011605.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.